Image (6b93b93c 685b 4ca0 8663 A9e90273c423 740 1)
Lamotrigine
Product Images NDC 53002-2513
7 FDA label images from Rpk Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 53002-2513). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (6b93b93c 685b 4ca0 8663 A9e90273c423 789 2)
The image shows four sets of Lamotrigine tablets by RPK Pharmaceuticals, Inc., each identified by shape, imprint, and strength: 25 mg white oblong tablets with 'U 111', 100 mg white oval tablets with 'U 112', 150 mg white triangular tablets with 'U 113', and 200 mg light blue triangular tablets with 'U 114'.*
Image (6b93b93c 685b 4ca0 8663 A9e90273c423 789 3)
Molecular Structure (Ad7af627 Ea4b 4a78 A71e Db1255416d1e 01)
Chemical structure of Lamotrigine, showing a triazine ring with amino groups and a dichlorophenyl substituent, representing the active ingredient in the product by RPK Pharmaceuticals, Inc.*
Figure 1 (Ad7af627 Ea4b 4a78 A71e Db1255416d1e 02)
A Kaplan-Meier failure probability graph comparing Lamotrigine and placebo treatments over weeks. The y-axis shows failure probability percentage, and the x-axis represents time in weeks. The chart includes censored data points indicated by plus signs along the curves.*
Figure 2 (Ad7af627 Ea4b 4a78 A71e Db1255416d1e 03)
A line graph showing failure probability (%) over time in weeks, comparing Lamotrigine and placebo groups. The plot includes stepwise curves for both groups and marks censored data points. The Lamotrigine group shows a lower failure probability compared to placebo throughout the study period lasting up to about 75 weeks.*
Label Image (Lbl530022513)
Lamotrigine 25 mg tablets packaging label from RPK Pharmaceuticals, Inc. The label shows a white 25 mg tablet bottle containing 100 tablets. It includes instructions to take as directed, prescription details, lot number, expiration date, and billing NDC information. The label also provides spaces for clinic and patient information.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
